54
DAFTAR PUSTAKA
Al-Qur’an dan Terjemahan (2004). Departemen Agama Republik Indonesia. Jakarta:
Toha Putra.
Abrams P, Cardozo L, Khoury S, Wein A. (2009). Incontinence 4th International Consultation on Incontinence. Paris: Editions 21.
Akbar A. (1988). Etika Kedokteran dalam Islam. Jakarta: Pustaka Antara.
Blaivas JG. (1985). Patophysiology of Lower Urinary Tract Dysfunction. Urol Clin North Am ;1292:215-24.
Blaivas JG. (1997). Definition and Classification of Urinary Incontinence:
Recommendations of The Urodynamic Society. NeuroUrol Urodyn;16(3):149- 51.
Chapple C, et al. (2013). OnabotulinumtoxinA 100 U significantly improves all Idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence A randomised, double-blind, placebo-controlled trial. Eur Urol; 64 (2) 249-56.
Dmochowski R, Chapple C, Nitti VW, et al (2010). OnabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. Dec;;184(6):2416-22.
Fakultas Kedokteran Indonesia (2014). Kapita Selekta Kedokteran. Edisi 4. Jakarta:
Media Aesculapius.
Fowler CJ, et al (2012). OnabotulinumtoxinA improves health – related quality of life in patients with urinary incontinence due to idiopathic overactive bladder A 36- week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol;62 148 57.
Goluboff ET, Chang DT, Olsson CA, Kaplan SA. (1995) Urodynamics and the etiology of postprostatectomy urinary incontinence: the initial Columbia experience. J Urol;153(3 Pt 2):1034-7.
Gufron U. (2013). Fiqih Orang Sakit. Cibubur: PT Enka Parahyangan.
Hadley HR, PE Zimmem. (1986). “The Treatment of Male Urinary Incontinence” in Campbell’s Urology, Walsh, Editor. London: WB Saunders. 1986 hal.2297- 3039.
Krisna, D.M dan Maulana (2018). Injeksi Botulinum untuk Tatalaksana Overactive Bladder. CDK-264 Vol. 45:5
Kuo HC. (2007). Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxina for idiopathic detrusor overactivity. J Urol.
178: 1359 - 63.
55
Majelis Ulama Indonesia (2012). Bahan Haram dalam Obat.
http://www.halalmui.org/newMUI/index.php/main/detil_page/11/375
Muhammad, J.H. dan Amri, A. (2009). Etika Kedokteran dan Hukum Kesehatan.
Edisi 4. Jakarta : EGC.
Payne CK. (2012). Conservative management of urinary urethral and pelvic devices.
In: Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia: Elsevier Saunders: p.2003-25.
Purnomo, B.B. (2012). Dasar-dasar Urologi, edisi ketiga. Jakarta: Sagung Seto Qaradhawi M. Y. (1995). Fatwa-fatwa Kontemporer Jilid 2. Jakarta: Gema Insani
Press.
Rahardjo HE, editor. (2012). Panduan tata laksana inkontinensia urin pada dewasa.
Perkumpulan Kontinensia Indonesia.
Rovner E, Dmochowski R, Chapple C, (2013). OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Neurourol Urodyn. Nov;;32(8):1109–15.
Schroder A, et al. (2010) European Association of Urology: Guidelines on Urinary Incontinence.
Smith CP, Somogyi GT. (2007). Botulinum toxin. In: Kreder K, Dmochowski R, editors. The overactive bladder: evaluation and management. Informa UK:
p.261-75.
Syabir, MU (2005). Pengobatan Alternatif Dalam Islam. Jakarta: Grafindo
Visco AG, et al. (2012) Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. November 8;;367(19):1803–13.
Zuhroni (2008). Pandangan Islam Terhadap Masalah Kedokteran dan Kesehatan.
Jakarta: Bagian Agama Islam UPT MKU Dan Bahasa Universitas YARSI.
